A new study at Los Alamos National Laboratory and in collaboration with Stanford Synchrotron Radiation Lightsource greatly improves scientists' understanding of the element actinium. The insights could support innovation in creating new classes of anticancer drugs.
"The short half-life of actinium-225 offers opportunity for new
alpha-emitting drugs to treat cancer, although very little has been known about
actinium because all of its isotopes are radioactive and have short
half-lives," said Maryline Ferrier, a Seaborg post-doctoral researcher on
the Los Alamos team. "This makes it hard to handle large enough quantities
of actinium to characterize its chemistry and bonding, which is critical for
designing chelators."
The
insights from this new study could provide the needed chemical information for
researchers to develop ways to bind actinium so that it can be safely
transported through the body to the tumor cell. "To build an appropriate
biological delivery system for actinium, there is a clear need to better
establish the chemical fundamentals for actinium," Ferrier said.
"Using only a few micrograms (approximately the weight of one grain of
sand) we were able to study actinium-containing compounds at the Stanford
Synchrotron Radiation Lightsource and at Los Alamos, and to study actinium in
various environments to understand its behavior in solution."
Read more at: http://phys.org/news/2016-08-isotope-possibilities-cancer-treatment.html#jCp